NCT05468060View on ClinicalTrials.gov

Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 28, 2020

Primary Completion Date

December 12, 2020

Study Completion Date

December 12, 2020

Conditions
Chronic HBV Infection
Interventions
DRUG

PA1010

Placebo as control

Trial Locations (1)

Unknown

Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

Zhejiang Palo Alto Pharmaceuticals, Inc.

INDUSTRY

NCT05468060 - Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects | Biotech Hunter | Biotech Hunter